Nature Communications (Mar 2017)
T cell costimulation blockade blunts pressure overload-induced heart failure
- Marinos Kallikourdis,
- Elisa Martini,
- Pierluigi Carullo,
- Claudia Sardi,
- Giuliana Roselli,
- Carolina M. Greco,
- Debora Vignali,
- Federica Riva,
- Anne Marie Ormbostad Berre,
- Tomas O. Stølen,
- Andrea Fumero,
- Giuseppe Faggian,
- Elisa Di Pasquale,
- Leonardo Elia,
- Cristiano Rumio,
- Daniele Catalucci,
- Roberto Papait,
- Gianluigi Condorelli
Affiliations
- Marinos Kallikourdis
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center
- Elisa Martini
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center
- Pierluigi Carullo
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center
- Claudia Sardi
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center
- Giuliana Roselli
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center
- Carolina M. Greco
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center
- Debora Vignali
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center
- Federica Riva
- Department of Veterinary Medicine (DIMEVET), Università degli Studi di Milano
- Anne Marie Ormbostad Berre
- Department of Circulation and Medical Imaging, KG Jebsen Centre of Medicine, Norwegian University of Science and Technology
- Tomas O. Stølen
- Department of Circulation and Medical Imaging, KG Jebsen Centre of Medicine, Norwegian University of Science and Technology
- Andrea Fumero
- Cardiac Surgery, Humanitas Clinical and Research Center
- Giuseppe Faggian
- Department of Cardiac Surgery, University of Verona
- Elisa Di Pasquale
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center
- Leonardo Elia
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center
- Cristiano Rumio
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano
- Daniele Catalucci
- Institute of Genetic and Biomedical Research (IRGB)—UOS of Milan, National Research Council of Italy
- Roberto Papait
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center
- Gianluigi Condorelli
- Department of Biomedical Sciences, Humanitas University
- DOI
- https://doi.org/10.1038/ncomms14680
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Abatacept is an FDA-approved drug used for treatment of rheumatoid arthritis. Here the authors show that abatacept reduces cardiomyocyte death in a mouse model of heart failure by inhibiting activation and heart infiltration of T cells and macrophages, an effect mediated by IL-10, suggesting a potential therapy for heart failure.
